tradingkey.logo
tradingkey.logo
Buscar

MaxCyte Inc

MXCT
Añadir a la lista de seguimiento
1.040USD
-0.050-4.59%
Cierre 05/15, 16:00ETCotizaciones retrasadas 15 min
111.41MCap. mercado
PérdidaP/E TTM

Más Datos de MaxCyte Inc Compañía

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Información de MaxCyte Inc

Símbolo de cotizaciónMXCT
Nombre de la empresaMaxCyte Inc
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)
Número de empleados114
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 29
Dirección9713 Key West Avenue,
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono13015175556
Sitio Webhttps://www.maxcyte.com/
Símbolo de cotizaciónMXCT
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)

Ejecutivos de MaxCyte Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%
Por regiónUSD
Nombre
Ganancia
Proporción
Inside the United States
21.08M
63.82%
Outside the United States
11.95M
36.18%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%

Estadísticas de accionistas

Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
Otro
71.83%
Accionistas
Accionistas
Proporción
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
Otro
71.83%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
28.60%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
8.15%
Private Equity
4.71%
Research Firm
3.93%
Individual Investor
1.37%
Venture Capital
0.32%
Pension Fund
0.21%
Bank and Trust
0.20%
Otro
31.76%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
292
79.92M
74.61%
-18.93M
2025Q4
282
79.65M
74.66%
-13.91M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capricorn Fund Managers Ltd
8.20M
7.67%
+8.20M
--
Jan 30, 2026
BlackRock Institutional Trust Company, N.A.
7.45M
6.98%
-585.24K
-7.28%
Dec 31, 2025
River Global Investors LLP
5.50M
5.14%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.72%
--
--
Dec 31, 2025
Cadian Capital Management LP
3.68M
3.45%
-4.54M
-55.24%
Dec 31, 2025
Mudita Advisors LLP
3.37M
3.15%
--
--
Dec 31, 2025
Morgan Stanley & Co. LLC
3.03M
2.84%
-1.22M
-28.66%
Dec 31, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
2.52M
2.36%
-41.34K
-1.62%
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.6%
iShares Micro-Cap ETF
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI